Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Myriad Genetics Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In early 2025, we entered into a strategic collaboration with PATHOMIQ, Inc. pursuant to which we obtained exclusive U.S. licen sing rights to PATHOMIQ's AI-enabled diagnostic platform, PATHOMIQ_PRAD, to enhance our oncology portfolio and offer AI-driven prognostic and predictive solutions for prostate cancer care.”
FILING10-K0000899923-26-000018cik 0000899923
“In September 2025, we entered into a strategic collaboration with SOPHiA GENETICS S.A. to develop a global liquid biopsy companion diagnostic solution.”
FILING10-K0000899923-26-000018cik 0000899923
“For example, in 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test, under its commercial, individual exchange and certain managed Medicaid plans.”
FILING10-K0000899923-26-000018cik 0000899923
“As part of the transaction, we licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and we licensed to Eurobio the rights to sell Prolaris in vitro diagnostic kits outside the U.S.”
FILING10-K0000899923-26-000018cik 0000899923
“For example, we license the rights from Eurobio Scientific to sell EndoPredict as a laboratory developed test outside of the European Union.”
FILING10-K0000899923-26-000018cik 0000899923
“For example, on February 1, 2024, we acquired the Precise Tumor Test and a CLIA certified laboratory from Intermountain Healthcare and on November 1, 2022, we acquired Gateway Genomics, LLC (Gateway), a personal genomics company and developer of consumer genetic tests that gives families genetic insight into their future children.”
FILING10-K0000899923-26-000018cik 0000899923
“For example, on February 1, 2024, we acquired the Precise Tumor Test and a CLIA certified laboratory from Intermountain Healthcare and on November 1, 2022, we acquired Gateway Genomics, LLC (Gateway), a personal genomics company and developer of consumer genetic tests that gives families genetic insight into their future children.”
FILING10-K0000899923-26-000018cik 0000899923
“In addition, in November 2020, we entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad") to in-license Myriad myChoice ® tumor testing in China.”
FILING20-F0001193125-26-183377cik 0001792267disclosed by BNR
“On July 31, 2025 (the "Closing Date"), we entered into Credit Agreement (the "Credit Agreement") with the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP., as administrative agent (the "Administrative Agent") and as initial lender ("OrbiMed").”
FILING10-K0000899923-26-000018cik 0000899923
“At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, we and our collaborators from the National Cancer Center Hospital East in Japan presented results from the MONSTAR-SCREEN 3 study, which reported 100 percent baseline sensitivity and highly sensitive detection of residual disease post-surgery.”
FILING10-K0000899923-26-000018cik 0000899923
Watchlist prices, news filtered to it, and its next report on your desk.
Myriad Genetics Inc has 7 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Myriad Genetics Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No intraday reading yet this session.
MYGN (Myriad Genetics Inc) has 7 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.